3 results
OX40 agonists have been shown to increase antitumor immunity and improve tumor-free survival in non-clinical models and OX40 agonist monoclonal antibodies (mAbs) are currently being evaluated in Phase I clinical trials. GSK3174998 is a humanized…
The primary objectives are to investigate whether L-carnitine infusion may rescue lipid-induced insulin resistance and whether L-carnitine infusion is improving metabolic flexibility in the state of lipid-induced insulin resistance. Furthermore,…
The primary objectives are to investigate which determinants (primarily carnitine status) determine the effect of carnitine supplementation on metabolic flexibility and insulin sensitivity in patients with type 2 diabetes. Furthermore, a secondary…